WuXi AppTec highlighted the strength of its integrated CRDMO model and growing exposure to late-stage and commercial assets as key drivers of sustained growth, Dr Minzhang Chen, co-CEO, said at the 44th Annual JP Morgan Healthcare Conference on 14 January 2026.
Presenting at the conference, Dr Chen pointed to strong preliminary 2025 results, with revenue reaching 45.5bn yuan, up 21.4% year-on-year from continuing operations. Adjusted non-IFRS net profit reached 15bn yuan, resulting in a net profit margin of 32.9%, up 5.9% points year on year. Backlog exceeded 55bn yuan, providing multi-year revenue visibility. “Our backlog provides strong visibility for the growth we are building”, he said. Full-year results and formal 2026 guidance will be released in March.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Dr Chen framed the performance as validation of WuXi AppTec’s end-to-end CRDMO platform, which supports customers from early drug discovery through clinical development and commercial manufacturing. The model enables internal conversion as molecules progress, strengthening relationships and positioning WuXi AppTec to capture value from high-quality, late-stage projects.
This dynamic is increasingly reflected in the pipeline. WuXi now supports more than 3,400 small-molecule CDMO projects, with a growing share of Phase III and commercial-stage drugs. Revenue from these late-stage assets has risen sharply, reflecting higher complexity and stronger customer partnerships.
Regulatory track record remains a differentiator, Dr Chen said. In 2025, the FDA approved 30 new small-molecule drugs, eight of which were supported by WuXi AppTec. Over the past five years, the company has supported around 21% of FDA-approved small-molecule new drugs and currently supports approximately one in seven commercial-stage GLP-1 drugs on the market, reinforcing its role in late-stage development and commercialisation.
The company also highlighted momentum in GLP-1, with the company currently supporting 24 GLP-1 drugs across clinical and commercial stages alongside momentum in peptide and Oligo therapies, with expanding capacity more than doubling in 2025 and enhanced capabilities positioning it to meet rising demand in these emerging modalities.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataClosing the presentation, Dr Chen said WuXi AppTec’s expanding late-stage exposure, strong internal conversion and record backlog position the company to deliver resilient growth and cash generation through industry cycles while continuing to invest in capacity and return capital to shareholders.
Sign up here to receive daily updates on the latest healthcare industry trends emerging from the JP Morgan Healthcare conference 2026. Sign up here to receive a comprehensive report after the conference.
